<DOC>
	<DOCNO>NCT01178411</DOCNO>
	<brief_summary>This extension study allow patient continue receive study treatment original study enrol reach designate end-dates .</brief_summary>
	<brief_title>An Extension Protocol Subjects Who Were Previously Enrolled Other ARQ 197 Protocols</brief_title>
	<detailed_description>This open label extension protocol patient treat previous ARQ 197 study reach designate end-dates . Patients enrol extension protocol receive either ARQ 197 monotherapy combination drug ( ) dose ( ) , schedule ( ) originally enrol . This extension study design evaluate safety tolerability ARQ 197 monotherapy combination drug ( ) give patient tolerate previous treatment well may benefit continue treatment . ARQ 197 administer twice daily , orally , meal ( regardless original protocol requirement ) .</detailed_description>
	<criteria>Signed write informed consent Study ARQ 197299 Male female subject age define original protocol enrol . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤3 Adequate bone marrow function : Absolute neutrophil count ( ANC ) ≥1.5 x 10^9/L Hemoglobin ≥8.0 g/dL Enrollment within 14 day completion End Treatment Visit original study Subjects , participate previous ARQ 197 study reach designate enddates , meet discontinuation criterion original study , may , opinion Investigator Sponsor , benefit treatment Women childbearing potential must negative pregnancy test perform within 14 day start study drug . Both men woman enrol study must agree use adequate birth control measure study Known suspect allergy ARQ 197 Substance abuse , medical , psychological social condition may interfere subject 's participation study evaluation study result Any condition unstable could jeopardize safety subject his/her compliance study A serious uncontrolled medical disorder/condition opinion Investigator would impair ability subject receive protocol therapy Requirement receive concurrent chemotherapy ( exclude combination therapy define original protocol ) , immunotherapy , radiotherapy , investigational drug study . Palliative radiotherapy allow provide : opinion Investigator , subject progressive disease radiation field encompass target lesion 10 % subject 's bone marrow irradiate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>melanoma</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>MiT tumor</keyword>
</DOC>